Prof. Dr. Erich Schlick (Director)
Wellington Partners
Dr. Erich Schlick studied medicine in Berlin, Mainz and Heidelberg.
He specialized in oncology and immunology at the US National Cancer Institute and holds a professorship in immune pharmacology at the University of Heidelberg.
In the 1990s, Dr. Schlick initiated the development of Humira, the first fully human therapeutic monoclonal antibody. His innovation became a blockbuster.
Before working in venture capital, he spent 15 years with BASF Pharma / Knoll AG, including ten years as an executive board member with worldwide responsibility for preclinical and clinical R&D.
In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira for the treatment of rheumatoid arthritis and other autoimmune diseases.
Dr. Schlick served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head of 3i Healthcare Worldwide. In 2005, he joined Wellington as an Investment Partner for Life Sciences and has since been responsible for many successful European biotech and medtech companies.
